TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12597653
Drug: Malathion 2
Normalized name: Malathion
DrugBank: Malathion (DB00772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Malathion 2 g/m2
Study: 12597653
Drug: Bifenthrin 25
Normalized name: Bifenthrin
DrugBank: Bifenthrin (DB15056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifenthrin 25 mg/m2 and 50 mg/m2
Study: 1906808
Drug: Bromocriptine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine with levodopa (combination therapy)
Study: 24948586
Drug: High-dose melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melphalan 200 mg/m(2) plus salvage ASCT
Study: 24948586
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide (400mg/m(2) per week for 12 weeks)
Study: 24948586
Drug: PAD induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAD induction therapy
Study: 22101219
Drug: Study agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study agent
Study: 17404152
Drug: Paclitaxel (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (225 mg/m(2) over 3 h every 3 weeks)
Study: 9572635
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of prednisolone for the first six months, followed by lower doses thereafter
Study: 9572635
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose glucocorticoid schedule after initial high doses
Study: 2657953
Drug: Paraghurt tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paraghurt tablets (freeze‐dried culture of Streptococcus faecium)
Study: 22406043
Drug: Sufentanil 0.2
Normalized name: ropivacaine-sufentanil 0.2%-1 mcg/mL-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0.2 ng/mL
Study: 22406043
Drug: Sufentanil 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0.3 ng/mL
Study: 22406043
Drug: Sufentanil 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0.4 ng/mL
Study: 17063980
Drug: Meloxicam 15
Normalized name: meloxicam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 15 mg (Merck S.A. Indústrias Químicas)
Study: 17063980
Drug: Movatec 15
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Movatec 15 mg (control formulation)
Study: 14670782
Drug: Dexamethasone as
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone as adjuvant therapy
Study: 10966840
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg FCHG49 glucosamine HCl, 800 mg TRH122 low molecular weight sodium chondroitin sulfate and 152 mg manganese ascorbate twice daily (Cosamin DS)
Study: 8867164
Drug: Peribulbar injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peribulbar injection
Study: 6422735
Drug: Propranolol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol plus lidoflazine (L)
Study: 6422735
Drug: Propranolol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol plus lidoflazine (L) after crossover
Study: 6422735
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Propranolol + Lidoflazine)
Study: 25803256
Drug: Flexible regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible regimen of daily risedronate (5 mg)
Study: 25803256
Drug: Fixed regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed regimen of daily risedronate (5 mg)
Study: 18240234
Drug: Oral azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azathioprine (AZA)
Study: 18240234
Drug: Intravenous pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pulse cyclophosphamide (CYC)
Study: 18240234
Drug: Low-dose corticosteroids
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose corticosteroids (CS) therapy
Study: 12745095
Drug: Theophylline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (200 mg IV)
Study: 8403634
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics and/or gentamicin (Septopal) antibiotic beads
Study: 31428854
Drug: G+1.50 (additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: G+1.50 (additional 1500 mL of water)
Study: 31428854
Drug: G+2.25 (additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: G+2.25 (additional 2250 mL of water)
Study: 31428854
Drug: G+0.50 (additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: G+0.50 (additional 500 mL of water)
Study: 31428854
Drug: G+1.00 (additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: G+1.00 (additional 1000 mL of water)
Study: 31428854
Drug: G+1.50 and
Approvals — FDA: no, EMA: no, PMDA: no
Description: G+1.50 and G+2.25
Study: 30191972
Drug: Avatrombopag (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avatrombopag (20 mg/day)
Study: 17000891
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH; 70 U/kg bolus)
Study: 21960699
Drug: Nebulized levalbuterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized levalbuterol 1.25 mg
Study: 10763958
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg p.o., b.i.d. for 1 month)
Study: 8881614
Drug: 0.25% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% hyperbaric bupivacaine (3.2‐3.6 ml, 8‐9 mg)
Study: 8881614
Drug: 0.25% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% hyperbaric bupivacaine (3.6‐4.0 ml, 9‐10 mg)
Study: 8881614
Drug: 0.25% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% hyperbaric bupivacaine (4.0‐4.4 ml, 10‐11 mg)
Study: 8881614
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (3.2‐3.6 ml, 8‐9 mg)
Study: 1357550
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol (50 micrograms, twice daily)
Study: 3082733
Drug: Supplementary parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementary parenteral nutrition (200 mg nitrogen per kg per day via central catheter)
Study: 3082733
Drug: Oral diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diet (40 kcal per kg per day)
Study: 3082733
Drug: Supplementary parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementary parenteral nutrition
Study: 20446755
Drug: Long-acting beta2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting beta2 agonists
Study: 18593773
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone replacement therapy in group A (22 patients)
Study: 18593773
Drug: Standard replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard replacement therapy without GH in group B (13 patients)
Study: 18830566
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg IV on admission, followed by 20 mg orally for 7 days
Study: 18830566
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no gastric acid inhibitor)
Study: 9757147
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ketoconazole twice a day plus 1.0 mg alprazolam
Study: 9757147
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ketoconazole twice a day plus 0.25 mg triazolam
Study: 9757147
Drug: ketoconazole placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketoconazole placebo plus 1.0 mg alprazolam
Study: 9757147
Drug: ketoconazole placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketoconazole placebo plus 0.25 mg triazolam
Study: 7923801
Drug: Naproxene Sodium
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxene Sodium (550 mg) 30 minutes before surgery
Study: 3410590
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Methyclothiazide with Triamterene (25, 50, 75 mg)
Study: 27129013
Drug: AZD3839 (1-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3839 (1-300 mg single oral doses)
Study: 22390677
Drug: Bacopa monnieri
Normalized name: BACOPA MONNIERI WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacopa monnieri (CDRI08 300 mg/day)
Study: 22390677
Drug: Pycnogenol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pycnogenol (150 mg/day)
Study: 19351782
Drug: Nicotrol nasal
Normalized name: Nicotrol Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotrol nasal spray (actual and expected doses varied)
Study: 16278986
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (125 mg capsules, twice a day for 10 days)
Study: 12133084
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam 10 mg (n=56)
Study: 7771834
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin E for 4 weeks, vitamin C and allopurinol 2 days before and 1 day after coronary artery bypass grafting (Group 1)
Study: 387216
Drug: Concurrent combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent combination therapy
Study: 975039
Drug: Single-drug chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-drug chemotherapy administered sequentially
Study: 23374147
Drug: Total Intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Intravenous Anesthesia with Target-Controlled Infusion (TIVA-TCI)
Study: 23374147
Drug: Balanced Inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced Inhalation Anesthesia (BAL)
Study: 19095858
Drug: CSE (intrathecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSE (intrathecal bupivacaine 2.5 mg with fentanyl 25 microg)
Study: 19095858
Drug: EPID (epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPID (epidural bupivacaine 2.5 mg/mL, 3 mL, followed by bupivacaine 1.25 mg/mL, 10 mL with fentanyl 50 microg)
Study: 11134829
Drug: Paracetamol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (20 mg/kg rectally)
Study: 9725547
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg cerivastatin daily for 7 days
Study: 7994829
Drug: Encainide or
Normalized name: encainide Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encainide or Flecainide (active therapy)
Study: 7994829
Drug: Moricizine (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moricizine (active therapy)
Study: 9855480
Drug: Cholecystokinin octapeptide
Normalized name: Cholecystokinin C-terminal octapeptide
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cholecystokinin octapeptide (CCK-8) infusion (4 ng/kg/min)
Study: 2680581
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg terbutaline powder by Bricanyl Turbuhaler
Study: 2680581
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg terbutaline by a conventional jet nebulizer (Pari Inhalierboy)
Study: 1092245
Drug: Ru‐Vert (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ru‐Vert (25 mg pentylenetetrazol, 12.5 mg pheniramine maleate, 50 mg nictonic acid) at a dosage of two tablets t.i.d.
Study: 25355774
Drug: Combined antibacterial
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antibacterial and fluoride therapy
Study: 23916716
Drug: Hyperfractionated radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiotherapy (RT) with cisplatin 20mg/m(2) chemotherapy on 5 consecutive days during weeks 1 and 5 or 6 of RT
Study: 19349314
Drug: Delta9‐Tetrahydrocannabinol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delta9‐Tetrahydrocannabinol (10 mg)
Study: 15232792
Drug: Special oral
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Special oral liquid nutritional supplement (Nepro)
Study: 15540421
Drug: Methotrexate (MT)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MT) 7.5-10.0 mg/week
Study: 15540421
Drug: Prednisolone (P)
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone (P) ≥ 10 mg/day + Methotrexate (MT)
Study: 11137255
Drug: ISCOM vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISCOM vaccines
Study: 11137255
Drug: Conventional non‐adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional non‐adjuvanted inactivated split virion vaccine
Study: 1606331
Drug: Ciprofloxacin 1
Normalized name: ciprofloxacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 1 g/d
Study: 1606331
Drug: Cimetidine 2400
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine 2400 mg/d
Study: 1606331
Drug: Ciprofloxacin 1
Normalized name: ciprofloxacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 1 g/d and Cimetidine 2400 mg/d (combined therapy)
Study: 1606331
Drug: Drug-free
Normalized name: HEAD CARE Proactive Health Drug-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free
Study: 25601762
Drug: Inhaled glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glucocorticoids (multiple doses)
Study: 23284074
Drug: lactate-based low-GDP
Normalized name: calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal Low Calcium 1.5]
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactate-based low-GDP solution
Study: 23284074
Drug: lactate-based high-GDP
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactate-based high-GDP solution
Study: 15780527
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) with estradiol 17‐valerate 2 mg for the first 11 days and estradiol 17‐valerate 2 mg plus ciproterone acetate 1 mg for the next 10 days, administered for 6 months
Study: 11517122
Drug: Continuous morphine
Normalized name: morphine sulfate Oral Suspension [MST Continus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous morphine (CM, 10 microg x kg(‐1) x h(‐1)) with three‐hourly placebo boluses
Study: 11517122
Drug: Intermittent morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent morphine (IM, 30 microg x kg(‐1) every 3 h) with a placebo infusion
Study: 11517122
Drug: Postoperative plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative plasma concentrations of insulin
Study: 10197215
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (2 mg)
Study: 10197215
Drug: Swallowed beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swallowed beclomethasone dipropionate (2 mg)
Study: 10197215
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose inhaler with large volume spacer (2 mg beclomethasone dipropionate)
Study: 3391341
Drug: Sleeping medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleeping medication alone
Study: 3391341
Drug: Sleeping medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleeping medication with 5.0 mg methscopolamine bromide
Study: 3391341
Drug: Methscopolamine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methscopolamine administration
Study: 31571853
Drug: Imidafenacin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidafenacin 0.1 mg
Study: 28781026
Drug: Low-Dose Statin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-Dose Statin + Armolipid Plus (n=50)
Study: 28781026
Drug: Low-Dose Statin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-Dose Statin (n=50)
Study: 21216310
Drug: HIVIS DNA
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIVIS DNA vaccine (arm B)
Study: 16626544
Drug: rhBNP (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhBNP (1.5 microg/kg bolus intravenous injection followed by 0.0075 microg.kg(‐1).mn(‐1) for the first 3 hours and 0.015‐0.03 microg.kg(‐1).mn(‐1) infusion for following 21 hours)
Study: 16626544
Drug: NIT (10
Normalized name: C1 esterase inhibitor 500 unit (10 mL) INTRAVEN KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIT (10 to 100 microg/mn intravenous infusion for 24 hours)
Study: 7943116
Drug: Butorphanol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol (1 to 2 mg hourly on request)
Study: 7943116
Drug: Fentanyl (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (50 to 100 micrograms hourly on request)
Study: 7943116
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (Butorphanol and Fentanyl)
Study: 3605567
Drug: Diazepam 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.25 mg/kg
Study: 28544222
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy including clarithromycin
Study: 24973894
Drug: Baclofen at
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baclofen at 80 mg/day
Study: 21318566
Drug: MDMA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (100 mg oral)
Study: 21318566
Drug: Methamphetamine (0.42
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methamphetamine (0.42 mg/kg oral)
Study: 19403636
Drug: Dietary Modification
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary Modification intervention (n = 19,541; daily goal: < or =20% of energy as fat, > or =5 servings of vegetables and fruit, and > or =6 servings of grains)
Study: 10592815
Drug: DTP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP and HibTITER administered concurrently
Study: 23871120
Drug: Errorless learning
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Errorless learning (ELL) and spaced retrieval (SR) cognitive techniques, trained twice a week for 4 weeks
Study: 11914101
Drug: l-NMMA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-NMMA (3 mg.h(‐1).kg(‐1))
Study: 1414897
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard diet and drug therapy)
Study: 31176289
Drug: Current guideline-driven
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current guideline-driven therapy
Study: 23469629
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for HCV (Pegylated interferon and Ribavirin)
Study: 23469629
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus Fluvastatin (80 mg/daily)
Study: 10224805
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 10 mg dydrogesterone twice daily
Study: 10224805
Drug: Intramuscular HCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular HCG administration 1500 IU every 4 days and 10 mg dydrogesterone twice daily
Study: 7972382
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of broad-spectrum sunscreens with low SPF
Study: 7972382
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of broad-spectrum sunscreens with increasing SPF
Study: 29549104
Drug: 1.8 mg
Normalized name: menthol 1.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mg of 0.1% E2 gel per day
Study: 29549104
Drug: Transdermal E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2 treatment
Study: 23186730
Drug: Aerobic dance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic dance classes (2 classes per week) and 30 minutes of daily self-imposed physical activity for 12 weeks
Study: 21195382
Drug: Oral doxycycline
Normalized name: doxycycline Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doxycycline plus metronidazole
Study: 21195382
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (observational cohort with additional 75 cases)
Study: 18499950
Drug: Preoperative education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative education and physical therapy (1 appointment with physiatrist, 2 practical classes with physiotherapist)
Study: 18499950
Drug: Preoperative education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative education and physical therapy
Study: 18499950
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no preoperative education and physical therapy)
Study: 16567641
Drug: Cortisone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisone (25 mg) administered orally 1 h before a socio-evaluative stressor
Study: 16567641
Drug: Cortisol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (10 mg), repeated oral administration 1 h before exposure to a spider photograph
Study: 14672103
Drug: Wearing a
Normalized name: Caladryl Clear
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Wearing a lucky garment, taking a test-preparation course, staying up late
Study: 10746528
Drug: Combined lumbar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined lumbar and sacral plexus block (30 mL lidocaine 1.33% with epinephrine for posterior lumbar plexus block, 10 mL same mixture for parasacral block, and 5 mL lidocaine 1% for iliac crest block)
Study: 10746528
Drug: Plain bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain bupivacaine spinal anesthesia (3 mL 0.5% plain bupivacaine)